Related Experiment Video
Updated: May 12, 2026

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice
Published on: April 1, 2015
Azathioprine as a substitute for 6-mercaptopurine in childhood acute lymphoblastic leukemia: a single-center
Jianhua Feng1, Wenya Qian1, Shuqin Shan1
1Department of Pediatric Hematology, The Affiliated Women and Children's Hospital of Ningbo University, Ningbo, China.
Abstract:
Azathioprine (AZA) is a prodrug that is converted into 6-mercaptopurine (6-MP). Due to the unavailability of 6-MP at our institution, we conducted a post hoc analysis to evaluate the feasibility of using AZA as an alternative therapeutic option across four clinical trials in childhood acute lymphoblastic leukemia (ALL). In total, 93 consecutively treated children with ALL were included. The 7-year overall survival and event-free survival rates were 93% and 87%, respectively. During maintenance therapy, 25 of 78 patients (32.1%) developed grade 1 hepatotoxicity. Among the 42 patients with available hematopoietic toxicity data for the entire maintenance period, the mean percentage of weeks with grade 3-4 leukopenia was 24%, while the mean percentage of weeks with grade 2-4 neutropenia was 44%. Taken together, AZA may serve as an effective alternative to 6-MP for the treatment of childhood ALL. However, enhanced monitoring of treatment-related toxicities is recommended during AZA-based therapy.
More Related Videos
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
06:28Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis
Published on: November 10, 2023
Related Concept Videos
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Pharmacokinetics in Pediatric Patients: Drug Excretion